CAG
FSTX

Crestwood Advisors Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Crestwood Advisors Group’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,204
Closed -$17K – 274
2020
Q3 		$17K Hold
3,204
– – ﹤0.01% 238
2020
Q2 		$19K Sell
3,204
-625
-16% -$3.61K ﹤0.01% 238
2020
Q1 		$14K Hold
3,829
– – ﹤0.01% 223
2019
Q4 		$24K Hold
3,829
– – ﹤0.01% 255
2019
Q3 		$53K Hold
3,829
– – ﹤0.01% 251
2019
Q2 		$57K Buy
+3,829
New +$103K ﹤0.01% 236

Other funds holding FSTX

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crestwood Advisors Group's FSTX Position: Q4 2020 in Review

Crestwood Advisors Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2020, closing a stake of 3,204 shares — an estimated $17K sold.

Crestwood Advisors Group first reported a position in FSTX in Q2 2019 and held it in 6 quarters. The position peaked at $57K in Q2 2019. 21 funds tracked by Wall St. Rank hold FSTX as of Q4 2020.

  • Crestwood Advisors Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Crestwood Advisors Group sold 3,204 F-star Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $17K.
  • Crestwood Advisors Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
  • Crestwood Advisors Group's F-star Therapeutics, Inc. Common Stock position peaked at $57K in Q2 2019.
  • 21 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Crestwood Advisors Group's 13F filing for Q4 2020, filed 9 Feb 2021.